malignant mesothelioma (mMS) - 1st line (L1) | malignant mesothelioma (mMS) - 2nd line (L2) | |
malignant mesothelioma (mMS) - 1st line (L1) | malignant mesothelioma (mMS) - 2nd line (L2) | |
immune chekpoint inhibitors | ||
anti-CTLA-4 | ||
tremelimumab | DETERMINE | |
anti-PD-(L)1 | ||
nivolumab based treatment | ||
nivolumab alone | ||
Immune checkpoint association | ||
nivolumab plus ipilimumab | CheckMate 743 |